Last checked at 20 Aug 2018 10:13
Creo Medical Group plc (the "Company")
Director/PDMR Dealing
The Company announces that on 17 August 2018, the Company was informed that, on 17 August and 15 August 2018 respectively, Craig Gulliford, Chief Executive Officer, and Chris Hancock, Chief Technology Officer, had part of their shareholdings dematerialised by a third party in order to procure that those shares are capable of being held in CREST. This process meant the transfer of a total of 960,000 ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") (representing 480,000 Ordinary Shares each) to Wealth Nominees Limited.
Following these transfers, Messrs Gulliford's and Hancock's beneficial interests in Ordinary Shares remain unchanged.
Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| Craig Gulliford | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Chief Executive Officer | ||||
b)
| Initial notification /Amendment
| Initial | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Creo Medical Group plc | ||||
b)
| LEI
| 213800H188ZDCWWXFA21 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
|
ordinary shares of 0.1 pence each
GB00BZ1BLL44 | ||||
b)
| Nature of the transaction
| Exercise of shares options and subsequent transfer of ordinary shares to SIPP via sale and purchase | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Price
| Transfer for nil consideration of 480,000 ordinary shares of 0.1 pence each to Wealth Nominees Limited in order to allow for such shares to be dematerialised and held in CREST
| ||||
e)
| Date of the transaction
| 17 August 2018 | ||||
f)
| Place of the transaction
| Off Market | ||||
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| Christopher Hancock | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| Chief Technical Officer | ||||
b)
| Initial notification /Amendment
| Initial | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Creo Medical Group plc | ||||
b)
| LEI
| 213800H188ZDCWWXFA21 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
|
ordinary shares of 0.1 pence each
GB00BZ1BLL44 | ||||
b)
| Nature of the transaction
| Exercise of shares options and subsequent transfer of ordinary shares to SIPP via sale and purchase | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information
- Aggregated volume
- Price | Transfer for nil consideration of 480,000 ordinary shares of 0.1 pence each to Wealth Nominees Limited in order to allow for such shares to be dematerialised and held in CREST
| ||||
e)
| Date of the transaction
| 15 August 2018 | ||||
f)
| Place of the transaction
| Off Market | ||||
Contacts
Creo Medical: | Cenkos: | FTI Consulting: |
Richard Rees +44 (0)129 160 6005 richard.rees@creomedical.com | Mark Connelly (NOMAD) Michael Johnson / Russell Kerr (Sales) +44 (0)207 397 8900 | Brett Pollard / Mo Noonan +44 (0)203 727 1000 creo@fticonsulting.com |
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring the CROMA surgical system to market through a suite of medical instruments which the Company has designed, initially for GI therapeutic endoscopy, an area with high unmet needs. The CROMA system will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, www.creomedical.com.